7.29  0.23 (3.26%)		04-17 16:00
Open: 7.105 High: 7.48 Volume: 427,553		Pre. Close: 7.06 Low: 7.05 Market Cap: 468(M)

Short term
Mid term
Targets	6-month :	8.73	1-year :	10.2
Resists	First :	7.48	Second :	8.73
Pivot price	6.76
Supports	First :	6.46	Second :	5.84
MAs	MA(5) :	7.08	MA(20) :	6.69
	MA(100) :	5.96	MA(250) :	6.09
MACD	MACD :	0.2	Signal :	0.2
%K %D	K(14,3) :	88.2	D(3) :	90.3
RSI	RSI(14): 70.9
52-week	High :	7.48	Low :	4.34

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AURA ] has closed below upper band by 4.6%. Bollinger Bands are 0.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.48 - 7.52	7.52 - 7.56
Low:	6.97 - 7	7 - 7.04
Close:	7.23 - 7.29	7.29 - 7.35

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Thu, 16 Apr 2026
Top Aura Biosciences Insider Makes Notable Move With Fresh Stock Sale - TipRanks

Thu, 16 Apr 2026
Insider sale: Aura Biosciences (NASDAQ: AURA) reports 12,079-share sale - Stock Titan

Thu, 16 Apr 2026
Aura Biosciences (AURA) insider’s RSU tax sale covers 11,738 shares at ~$7 - Stock Titan

Tue, 14 Apr 2026
Is Aura Biosciences (AURA) stock outpacing its medical peers this year? - MSN

Fri, 10 Apr 2026
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy? - qz.com

Thu, 09 Apr 2026
Aura Biosciences, Inc. (AURA) Recently Triggered a Golden Cross Signal: Is It Time to Invest? - Bitget

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	64 (M)
Shares Float	36 (M)
Held by Insiders	2.4 (%)
Held by Institutions	85.4 (%)
Shares Short	2,510 (K)
Shares Short P.Month	2,890 (K)

EPS	-1.91
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.49
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-35.9 %
Return on Equity (ttm)	-64.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.77
Qtrly Earnings Growth	0 %
Operating Cash Flow	-88 (M)
Levered Free Cash Flow	-51 (M)

PE Ratio	-3.82
PEG Ratio	0
Price to Book value	2.92
Price to Sales	0
Price to Cash Flow	-5.25

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.